Scisparc-clearmind medicine collaboration announces the publication of european patent application for binge behavior psychedelic combination treatment

Tel aviv, israel, jan. 06, 2025 (globe newswire) -- scisparc ltd. (nasdaq: sprc) ("company" or "scisparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today as part of its ongoing collaboration with clearmind medicine inc. (“clearmind”) (nasdaq: cmnd) (fse: cwy0), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, the publication of a european patent application submitted by clearmind under the european patent office for innovative combination therapy of meai and n-acylethanolamines, to binge behavior including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct.
SPRC Ratings Summary
SPRC Quant Ranking